Skip to main content

Galecto, Inc. (GLTO)

NASDAQ: GLTO · IEX Real-Time Price · USD
3.81
-0.04 (-1.04%)
After-hours:Sep 24, 2021 7:12 PM EDT
3.85
0.00 (0.00%)
At close: Sep 24, 4:00 PM
Market Cap97.26M
Revenue (ttm)n/a
Net Income (ttm)-43.94M
Shares Out25.26M
EPS (ttm)-2.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume43,713
Open3.85
Previous Close3.85
Day's Range3.82 - 3.92
52-Week Range3.80 - 17.99
Betan/a
AnalystsStrong Buy
Price Target13.00 (+237.7%)
Est. Earnings DateNov 4, 2021

About GLTO

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral ...

IndustryBiotechnology
IPO DateOct 29, 2020
Employees28
Stock ExchangeNASDAQ
Ticker SymbolGLTO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for Galecto stock is "Strong Buy." The 12-month stock price forecast is 13.00, which is an increase of 237.66% from the latest price.

Price Target
$13.00
(237.66% upside)
Analyst Consensus: Strong Buy

News

Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference

BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced th...

1 week ago - GlobeNewsWire

Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indications Galecto now has three ongoing Phase 2 clinical trials with three different drug...

1 week ago - GlobeNewsWire

Galecto Starts Dosing In Mid-Stage Myelofibrosis Trial

Galecto Inc (NASDAQ: GLTO) has announced the treatment of the first patient in a Phase 2a trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis.  Myelofibrosis, a form of chronic leukemia, is a rare...

1 month ago - Benzinga

Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MY...

BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the treatment of t...

1 month ago - GlobeNewsWire

Galecto Reports Second Quarter Operating and Financial Results

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its...

1 month ago - GlobeNewsWire

3 Net Current Asset Value Stock Picks

There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can make huge margins of return out of these stocks after the market h...

Other symbols:DSSSVRA
2 months ago - GuruFocus

Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced th...

2 months ago - GlobeNewsWire

Galecto's GB0139 Shows Favorable Safety and Tolerability Profile with Promising Changes in Efficacy Markers in Hospit...

BOSTON and COPENHAGEN, Denmark, June 22, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed, clinical stage biotechnology company focused on the development of novel treatments for...

3 months ago - GlobeNewsWire

Galecto Hosting Expert Perspectives Webinar on the Current Myelofibrosis Treatment Landscape and Potential Future Tre...

Webinar on Wednesday, June 9th @ 8amET Webinar on Wednesday, June 9th @ 8amET

3 months ago - GlobeNewsWire

Galecto Reports First Quarter Financial Results and Provides a Corporate Update

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its ...

4 months ago - GlobeNewsWire

Galecto (GLTO) Enters Oversold Territory

Galecto (GLTO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

5 months ago - Zacks Investment Research

Galecto Reports Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update

BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it...

5 months ago - GlobeNewsWire

UPDATE: Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosi...

Tuesday, March 30, 2021 @ 2pm Eastern Time Tuesday, March 30, 2021 @ 2pm Eastern Time

6 months ago - GlobeNewsWire

Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Po...

Tuesday, March 30, 2021 @ 2pm Eastern Time. Tuesday, March 30, 2021 @ 2pm Eastern Time.

6 months ago - GlobeNewsWire

Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for I...

Galecto expects to continue dosing patients in the 3 mg arm, whereas the 10 mg arm and combinations with nintedanib or pirfenidone will be discontinued at the recommendation of the DSMB Galecto expects ...

6 months ago - GlobeNewsWire

Galecto to Present at Upcoming Investor Conferences

BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced Hans Schambye, the...

7 months ago - GlobeNewsWire

Galecto Appoints Anne Prener to its Board of Directors

BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the ...

8 months ago - GlobeNewsWire

Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that...

8 months ago - GlobeNewsWire

Galecto Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update

Successfully completed listing on US Nasdaq and raised over $ 150 million during recent IPO and preceding crossover round

9 months ago - GlobeNewsWire

Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showin...

BOSTON and COPENHAGEN, Denmark, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc., a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced t...

9 months ago - GlobeNewsWire

Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors

BOSTON and COPENHAGEN, Denmark, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and can...

10 months ago - GlobeNewsWire

U.S. IPO Week Ahead: The IPO Market Takes A Break During The Shortened Holiday Week

The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to raise $750 mil...

10 months ago - Seeking Alpha

U.S. IPO Weekly Recap: Big Fintechs Fall As 11 IPOs Squeeze In Ahead Of The Election

Eleven IPOs and nine SPACs priced this past week, getting out ahead of the US election. Markets tumbled and volatility spiked, as several deals broke issue and three IPOs postponed.

Other symbols:AVIRLESLMAXROOT
10 months ago - Seeking Alpha

Galecto Announces Pricing of Initial Public Offering

BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the biological ...

10 months ago - GlobeNewsWire

Galecto Finalizes Plan For $85 Million IPO

Galecto has filed proposed terms for an $85 million U.S. IPO. The firm is development treatments for various fibrosis diseases.

11 months ago - Seeking Alpha